Emergent Stability Testing for HIV Adenoviral Vaccine Candidates

The National Institute of Allergy and Infectious Diseases (NIAID) intends to award a sole source, firm-fixed price purchase order to Emergent Product Development Gaithersburg Inc. for the maintenance of Biologics Master File 018816 and Biologics Master File 14883. These master files are crucial for NIAID to update its Investigational New Drug (IND) application 030255 related to HIV Adenoviral Vaccine Candidates. Emergent owns both master files and is the only vendor with access to the necessary information. The contract, under NAICS code 541714 (Research and Development in Biotechnology), will cover stability testing and annual report submissions from April 27, 2026, to March 31, 2029, including option years. While this is a notice of intent and not a request for competitive proposals, other interested vendors may submit capability statements by April 23, 2026, for evaluation, though the government maintains discretion on whether to compete the requirement.